We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




CRP Levels Modulate Hypertension in Mouse Model

By Biotechdaily staff writers
Posted on 28 Feb 2007
Researchers have found that C-reactive protein (CRP), a protein biomarker commonly assayed as a predictor of hypertension and other forms of cardiovascular disease, actually plays a role in the development of hypertension.

Investigators at the University of Texas Southwestern Medical School (Dallas, USA) worked with a population of mice that had been genetically engineered to express a rabbit gene for CRP synthesis. More...
Mice of the same strain without the rabbit gene formed the control group. The rabbit gene was under regulatory control of the mouse phosphoenolpyruvate carboxykinase promoter gene that in turn was responsive to changes in dietary carbohydrate intake. Altering the animals' diets modulated production of CRP by their livers. Throughout the study conscious blood pressure (BP) measurements were performed by radiotelemetry.

Results published in the February 2007 issue of Circulation revealed that compared with controls, the engineered mice had hypertension that was predominantly systolic, and the severity of hypertension varied in parallel with changes in CRP levels modulated by dietary manipulation. The mice were shown to be sensitive to angiotensin II, which is a major circulating factor regulating blood pressure via arterial constriction. This was due to alterations in key proteins in the vascular wall that are regulated by angiotensin II.

"We found that when we switched on the gene that causes increases in CRP, the blood pressure went up, and when we turned off the gene and CRP levels went down, the blood pressure fell. Diet changes in the control mice had no effect, indicating that the blood pressure responses were due to CRP,” said senior author Dr. Wanpen Vongpatanasin, associate professor of internal medicine at the University of Texas Southwestern Medical. "Whether these same processes are operative in humans is yet to be determined. We are also pursuing follow-up studies to further understand better how CRP causes the high blood pressure in the mice.”


Related Links:
University of Texas Southwestern Medical School

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.